protein PEDF utilizing delivery methods other than gene therapy. The grant of the exclusive license proposed does not supercede that previously announced in 62 FR 62781–62782, November 25, 1997.

DATES: Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before July 1, 2002, will be considered.

ADDRESSES: Requests for a copy of these patent applications, inquiries, comments and other materials relating to the contemplated license should be directed to Susan S. Rucker, J.D., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3821; telephone: 301/496–7056 ext 245; fax: 301/402–0220. A signed Confidentiality Agreement (CDA) will be required to receive copies of the patent applications.

SUPPLEMENTARY INFORMATION: The patents and patent applications describe and claim compositions based on the molecule known as Pigment Epithelium Derived Factor (PEDF) and methods for making and using those compositions. PEDF is also known as EPC–1 (early population doubling level cDNA–1; RJ Pignolo, et al. J Biol Chem. 268(12):8949–57 (Apr 25, 1993)) and SLED (Bouck, et al. WO 99/04806 (2/4/99)). These methods and compositions include the protein, as well as recombinant applications thereof based on the amino acid and nucleic acid sequences of PEDF. PEDF is a member of the serpin (serine protease inhibitor) superfamily of proteins but has not been shown to posses the serine protease inhibitory properties. *In vitro* studies have demonstrated that PEDF has properties beneficial to neuronal tissue (neuronal cell survival, gliastatic, and neurotrophic activity) and anti-angiogenic properties. These properties suggest that PEDF may be useful in compositions and methods for the treatment of ocular diseases such as age-related macular degeneration and diabetic retinopathy which may be related to angiogenesis and neuronal tissue properties or in the treatment of cancers.

The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. This prospective exclusive license may be granted unless within sixty (60) days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Applications for a license (*i.e.,* a completed ''Application for License to Public Health Service Inventions'') in the indicated exclusive field of use filed in response to this notice will be treated as objections to the grant of the contemplated license. Any objections to the grant of the contemplated license must specifically and separately, if more than one Notice of Intent to Grant related to these patents and patent applications is being responded to, reference the particular Notice of Intent to Grant being responded to and address only the proposed grant as set forth in the particular Notice of Intent to grant (*i.e.,* an objection to the proposed grant as set forth in this Notice of Intent to Grant to EyeTech Pharmaceuticals, Incorporated will not be considered an objection to the proposed grant as set forth in the concurrently published Notice of Intent to Grant to GenVec, Incorporated). Comments and objections will not be made available for public inspection and, to the extent permitted by law, will not be subject to disclosure under the Freedom of Information Act 35 U.S.C. 552.

Dated: April 24, 2002.

Jack Spiegel,

Director, Division of Technology Development and Transfer, Office of Technology Transfer.

[FR Doc. 02–10928 Filed 5–1–02; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive License: Delivery of Pigment Epithelium Derived Factor (PEDF) To Treat Cancer by Gene Therapy

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance with 15 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive world-wide license to practice the inventions embodied in any or all of (a) U.S. patents 5,840,686 (11/24/1998) and 6,319,687 (11/20/2001), (b) U.S. patent applications 07/894,215 (06/04/1992, now abandoned), 07/952,796 (9/24/1992, now abandoned), 08/279,979 (7/25/1994, now abandoned), 08/377,710 (01/25/1995, now abandoned), 08/520,373 (8/29/1995) and 09/630,629 (8/1/2000), and (c) foreign applications corresponding to PCT Patent Applications (i) PCT/US93/05358 entitled ''Retinal Pigmented Epithelium Derived Neurotrophic Factor'', published as WO 93/24529 (12/9/1993) and (ii) PCT/US95/07201, entitled ''Pigment Epithelium-Derived Factor: Characterization, Genomic Organization and Sequence of the PEDF Gene'', published as WO 95/33480 (12/14/95) to GenVec, Incorporated of Gaithersburg, Maryland.

The prospective exclusive license may be limited to the development of compositions and methods utilizing viral vector based gene therapy for the delivery of PEDF in the treatment of cancer. The grant of the exclusive license proposed does not supercede that previously announced in 62 FR 62781–62782, November 25, 1997.

DATES: Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before July 1, 2002, will be considered.

ADDRESSES: Requests for a copy of these patent applications, inquiries, comments and other materials relating to the contemplated license should be directed to Susan S. Rucker, J.D., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3821; telephone: 301/496–7056 ext 245; fax: 301/402–0220. A signed Confidentiality Agreement (CDA) will be required to receive copies of the patent applications.

SUPPLEMENTARY INFORMATION: The patents and patent applications describe and claim compositions and methods that incorporate the molecule known as Pigment Epithelium Derived Factor (PEDF). PEDF is also known as EPC–1 (early population doubling level cDNA–1; RJ Pignolo, et al. J Biol Chem. 268(12): 8949–57 (Apr. 25, 1993)) and SLED (Bouck, et al. WO 99/04806 (2/4/99)). These methods and compositions incorporating the molecule PEDF include the protein, as well as recombinant applications thereof based on the amino acid and nucleic acid sequences, for the molecule. PEDF is a member of the serpin (serine protease inhibitor) superfamily of proteins but has not been shown to posses the serine protease inhibitory properties. *In vitro* studies have demonstrated that PEDF has properties beneficial to neuronal tissue (neuronal cell survival, gliastatic, and neurotrophic activity) and anti-angiogenic properties. These properties suggest that PEDF may be useful in compositions and methods for the

treatment of cancers or in the treatment of ocular diseases such as age-related macular degeneration and diabetic retinopathy, which may be related to both angiogenesis and the neuronal tissue properties of the eye.

The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. This prospective exclusive license may be granted unless within sixty (60) days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Applications for a license (*i.e.,* a completed ''Application for License to Public Health Service Inventions'') in the indicated exclusive field of use filed in response to this notice will be treated as objections to the grant of the contemplated license. Any objections to the grant of the contemplated license must specifically and separately, if more than one Notice of Intent to Grant related to these patents and patent applications is being responded to, reference the particular Notice of Intent to Grant being responded to and address only the proposed grant as set forth in the particular Notice of Intent to Grant (*i.e.,* an objection to the proposed grant as set forth in this Notice of Intent to Grant to GenVec, Incorporated will not be considered an objection to the proposed grant as set forth in the concurrently published Notice of Intent to Grant to EyeTech Pharmaceuticals, Incorporated). Comments and objections will not be made available for public inspection and, to the extent permitted by law, will not be subject to disclosure under the Freedom of Information Act 35 U.S.C. 552.

Dated: April 24, 2002.

Jack Spiegel,

Director, Division of Technology Development and Transfer, Office of Technology Transfer.

[FR Doc. 02–10929 Filed 5–1–02; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF THE INTERIOR

Office of American Indian Trust

Agency Information Collection Activities Under OMB Review

AGENCY: Office of American Indian Trust, Interior.

ACTION: Notice.

SUMMARY: In compliance with the Paperwork Reduction Act, this notice announces that the Information Collection Request (ICR) abstracted below has been forwarded to the Office of Management and Budget (OMB) for review and renewal.

DATES: Comment must be received on or before June 3, 2002.

ADDRESSES: Comments should be sent to: Document Library, Room 10102, Attn: Desk Officer for the Department of the Interior, Office of Information and Regulatory Affairs, Office of Management and Budget, 725 17th Street NW., Washington, DC 20503. Copies of any comments should be sent to: Director, Office of American Indian Trust, United States Department of the Interior, 1849 C Street, NW., Room 2472, Washington, DC 20240.

FOR FURTHER INFORMATION CONTACT: James I. Pace, (202) 208–3338.

SUPPLEMENTARY INFORMATION: The Department of the Interior invites comments by the public on: Whether the validity of the methodology and assumptions used; ways to enhance the quality, usefulness, and clarity of the information to be collected; and minimizing the burden of collection on those who are to respond. The Information Collection Request describes the nature of the information collection and its expected cost and burden. OMB has up to 60 days to approve or disapprove this information collection but may respond after 30 days; therefore, public comments submitted to OMB closer to 30 days will have more chance for review. An Agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. The OMB control number for this collection is 1076–0146. The **Federal Register** Notice with a 60-day comment period soliciting comments on this collection of information was published on February 14, 2002 (67 FR 6941). There were no comments received.

Title: Evaluation of the Performance of Trust Functions Performed by Tribes under Self-Governance Compacts, 25 CFR part 1000, subpart O (OMB Control No. 1076–0146). This is a request for an extension of a currently approved information collection.

Abstract: This collection of information will be made to ensure compliance with 25 U.S.C. 458cc(d) which requires that the Secretary of the Interior monitor the performance of trust functions which have been assumed under Self-Governance funding agreements negotiated between the Secretary and an Indian Tribe/Consortia (hereinafter the respondent).

This information collection addresses those statutory and regulatory performance requirements imposed upon the respondent through the assumption of a particular trust function, through a formal Self-Governance agreement pursuant to the Self-Governance Act (Pub. L. 103–413) which, if not performed properly, may create imminent jeopardy to a trust asset. The information will be used by the Department of the Interior to determine if there is imminent jeopardy to any asset held in trust by the United States for an Indian Tribe or individual Indian that are being managed by a Tribe/Consortium on behalf of the United States pursuant to a Self-Governance agreement.

Burden Statement: There is no preliminary work nor is any follow-up work required of the respondents. There are no forms to complete. The annual hour burden is calculated by the amount of time that the reviewer spends at each program site interviewing the respondents and collecting file information. Currently there are 70 respondents. The time required ranges from 4 person/hours to 80 person/hours. Based on the size and complexity of the current programs, the average hours spent for each annual evaluation is estimated at 24 person/hours. $70 \times 24 = 1{,}680$ total burden hours per year for the collection of information.

Dated: April 18, 2002.

Neal A. McCaleb,

Assistant Secretary—Indian Affairs.

[FR Doc. 02–10802 Filed 5–1–02; 8:45 am]

BILLING CODE 4310–E8–P

DEPARTMENT OF THE INTERIOR

Fish and Wildlife Service

Information Collections Submitted to the Office of Management and Budget for Approval Under the Paperwork Reduction Act; Grants Programs Authorized by the North American Wetlands Conservation Act (NAWCA)

AGENCY: Fish and Wildlife Service, Interior.

ACTION: Notice of information collection; request for comments.

SUMMARY: The U.S. Fish and Wildlife Service (Service) plans to submit to the Office of Management and Budget (OMB) for approval under the provisions of the Paperwork Reduction Act of 1995. Copies of the specific information collection requirements, related forms and explanatory material may be obtained by contacting the Service Information Collection